Search - tctmd.com

Displaying 21 - 30 of 30

Sort: Relevancy | Date

Presentation TCT 2015

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Presenter: George D. Dangas, Paul A. Gurbel, Joshua W. Knowles

October 13, 2015

Presentation TCT 2015

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Giora Weisz

October 13, 2015

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2015

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein

October 13, 2015

Presentation TCT 2015

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron

October 13, 2015

Presentation TCT 2015

Will PCSK9 Inhibitors Transform the Natural History of Atherosclerosis?

Presenter: Gregg W. Stone, Renu Virmani, Philippe Gabriel Steg

October 12, 2015

Presentation TCT 2014

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran, Evan A. Stein

September 15, 2014

Presentation TCT 2014

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

Presenter: Valentin Fuster, Patrick W. Serruys, Harvey D. White

September 14, 2014

Presentation TCT 2013

PCSK9 Inhibitors: Too Good to Be True?

Presenter: Evan Stein

October 30, 2013

Presentation TCT 2012

PCSK9 Inhibitors: The Holy Grail?

Presenter: Evan Stein

October 23, 2012

Advertisement

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Will PCSK9 Inhibitors Transform the Natural History of Atherosclerosis?

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

PCSK9 Inhibitors: Too Good to Be True?

PCSK9 Inhibitors: The Holy Grail?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content